Try GOLD - Free

Swiggy scales up Noice to expand private-label play

Mint Chennai

|

January 12, 2026

Swiggy’s Noice expanded its supplier base from 40 to nearly 70 contract manufacturers

- salman SH salman.hameeth@livemint.com

Swiggy scales up Noice to expand private-label play

The brand has moved beyond premium snacks and sweets, adding dairy, eggs, fresh foods, beverages and ready-to-cook items.

(REUTERS)

Swiggy’s private-label brand, Noice, which debuted on its quick-commerce platform Instamart, has expanded rapidly by adding contract manufacturers across various categories, including bakery, snacks, confectionery, dairy, eggs and perishable foods.

The push expanded Noice’s range and supplier base since August 2025. Two people aware of the company’s operations said Noice has grown from about 200 stock-keeping units (SKUs) to about 350 now, and from about 40 contract manufacturers to close to 70 over the same period, as Swiggy adds products across new categories.

What began as a small-batch, premium range, centred on Indian sweets, snacks, cookies, baked items sourced from small kitchens and manufacturers—has widened sharply in recent months as Noice adds more categories and partners, said the second person aware of Instamart’s operations.

“Recent additions include beverages, ready-to-cook items, and dairy and fresh items like eggs, dosa batter and paneer,” the person added.

MORE STORIES FROM Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size